AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aytu BioPharma, Inc. (AYTU) on January 5, 2023, reporting events occurring on January 4, 2023. The filing addresses a material modification to the rights of security holders regarding a reverse stock split previously approved by stockholders on October 5, 2022.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Board approved a 1-for-20 reverse stock split effective at 12:01 a.m. Eastern Time on January 6, 2023.
- Share Count: Immediately following the split, approximately 3.4 million shares of common stock will be issued and outstanding.
- Fractional Shares: No fractional shares will be issued; holders will receive cash in lieu of fractional interests, with share counts rounded down to the next whole number.
- Trading Details: Shares will trade on a split-adjusted basis on the Nasdaq Capital Market under the symbol "AYTU" with a new CUSIP number (054754858) starting January 6, 2023.
- Derivatives: All outstanding stock options and warrants will be proportionally adjusted.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard qualification that the discussion is subject to the full text of the Certificate of Amendment. The primary operational change is the mechanical adjustment of the capital structure.
Investor Verification Checklist
- Verify the effective date and time of the 1-for-20 reverse stock split (January 6, 2023, 12:01 a.m. ET).
- Confirm the new CUSIP number (054754858) for post-split trading.
- Check brokerage account statements for the automatic adjustment of share positions and any cash payments for fractional shares.
- Review the adjustment of any held stock options or warrants to ensure proportional alignment with the split.
- Confirm the post-split share count of approximately 3.4 million shares.